Major Events - Four Seasons Pharmaceutical (00460) invests in Swiss Suisselle to accelerate global medical aesthetics business expansion [1] - Basilea Pharmaceutica-B (02616) to announce Phase I dose-escalation clinical data for PD-1/VEGF/CTLA-4 triple antibody and latest research design for ROR1 ADC [1] - Hengrui Medicine (01276) subsidiary receives drug clinical trial approval notice [1] - Huajian Medical (01931) acquires U.S. property and establishes U.S. subsidiary ETHK BANK to promote stablecoins and intellectual property securitization in the U.S. [1] - China National Pharmaceutical Group (01177): TQB2102 "HER2 dual antibody ADC" included in breakthrough therapy designation program [1] Operating Performance - 361 Degrees (01361): Retail sales of 361° main brand products in Q3 increased by approximately 10% year-on-year [1] - Xinhua Insurance (01336) expects net profit attributable to shareholders for the first three quarters to increase by 45% to 65% year-on-year [1] - Country Garden (02007) achieved contract sales amounting to approximately 2.58 billion yuan in September [1] - Dekang Agriculture and Animal Husbandry (02419) sold approximately 7.55 million pigs and generated sales revenue of approximately 14.28 billion yuan in the first nine months [1] - Longfor Group (00960) achieved total contract sales amount of 50.75 billion yuan in the first nine months [1]

Investment Rating - The report suggests a positive outlook for the oligonucleotide drug industry, indicating that it is on the verge of a therapeutic paradigm revolution, particularly in the treatment of common diseases [3]. Core Insights - The oligonucleotide drug market is approaching a critical point of explosion, with significant advancements in delivery technologies and therapeutic targets [3]. - The report highlights the potential for multiple innovative treatment paradigms for common liver diseases over the next five years, focusing on lipid-lowering, blood pressure reduction, and hepatitis B [3]. - The report emphasizes the importance of differentiated delivery technologies and the potential for business development (BD) opportunities in the industry [3]. Summary by Sections Industry Overview - The report revisits the previous assessment from January 2021, which predicted that oligonucleotide drugs would become the third major class of therapeutics after small molecules and monoclonal antibodies [3]. - It notes that the market has seen a significant increase in the number of approved siRNA/ASO drugs since 2022, addressing unmet medical needs [4]. Market Dynamics - The report identifies key players in the industry, including Alnylam, Arrowhead, and Ionis, and discusses their market capitalization changes from 2021 to 2025, highlighting Alnylam's significant growth due to successful drug launches [7]. - It mentions that the market for oligonucleotide drugs is expanding into common diseases, with Alnylam's drugs like Amvuttra and Inclisiran showing strong sales potential [20]. Technological Advancements - The report discusses advancements in delivery technologies, particularly the GalNAc conjugation platform, which has significantly improved the efficacy and safety of oligonucleotide drugs [41][42]. - It highlights the ongoing research into dual-target oligonucleotide drugs, which may become a new trend in the industry [36]. Competitive Landscape - The report outlines the competitive landscape, noting that multinational corporations (MNCs) are actively acquiring clinical-stage FIC drugs and exploring collaborations with biotech firms [3]. - It emphasizes the need for targeted delivery systems for different organs, indicating that the advancement and differentiation of delivery platforms will be crucial for the future success of oligonucleotide drug companies [26][27].

Core Insights - The recent surge in Business Development (BD) transactions among domestic innovative drug companies is entering a milestone payment phase, with several companies announcing significant payments triggered by clinical trial achievements [1][2][3] Group 1: Milestone Payments - BaiLi Tianheng announced a milestone payment of $250 million from Bristol-Myers Squibb (BMS) following the success of its global Phase II/III clinical trial for IZABRIGHT-Breast01 [1][3] - This payment is part of a larger agreement where BaiLi Tianheng could receive up to $2.5 billion in total milestone payments, including previous payments from BMS [4] - Other companies, such as China National Pharmaceutical Group and Yiming Oncology-B, have also reported receiving milestone payments, indicating a trend in the industry [2][3] Group 2: Market Trends and Future Outlook - UBS Securities predicts that the current high enthusiasm for BD transactions will gradually decline, shifting market focus towards fundamental revenue and profit growth [2][6] - The sustainability of revenue and profit growth for companies that have engaged in licensing deals will depend on the innovation and commercialization potential of their pipelines [2][5] - A significant number of past BD transactions have faced challenges, with a notable "return rate" of 40% for deals completed in 2020, indicating potential risks in future payments and commercialization [6][7] Group 3: Clinical Trials and Regulatory Status - BaiLi Tianheng is conducting over 40 clinical trials in China and the U.S. for its drug izabren, with several trials receiving breakthrough therapy designations from regulatory authorities [5] - The company has also secured a priority review designation for izabren from the National Medical Products Administration in China, enhancing its market prospects [5]

Macroeconomic Dynamics - Domestic gasoline and diesel prices will be reduced by 70 yuan and 75 yuan per ton respectively starting from October 13, 2023, due to the decline in international oil prices, resulting in a decrease of 0.06 yuan per liter for 92 and 95 gasoline and 0 diesel [2] - In the first three quarters, China's exports of high-tech products reached 3.75 trillion yuan, an increase of 11.9%, contributing over 30% to the overall export growth [5] International Relations - The Chinese Foreign Ministry criticized the U.S. for threatening to impose 100% tariffs on Chinese goods in retaliation for China's rare earth export controls, emphasizing that this approach is not the correct way to engage with China [3] - The Chinese Foreign Ministry clarified that recent export control measures on rare earths are unrelated to Pakistan's cooperation with the U.S. and are part of China's legal framework to enhance its export control system [4] Financial Institutions - UBS indicated that if the MSCI China Index drops to 74, it will find strong support, with investors likely to buy on dips, as the index has risen 36% since April [7] - New China Life Insurance expects a net profit increase of 45% to 65% year-on-year for the first three quarters of 2025, driven by reforms and improved asset allocation [9] - Everbright Bank plans to grant a comprehensive credit limit of 29 billion yuan to CITIC Financial Asset Management, constituting a related party transaction [10] - Bank of America raised its gold price forecast for next year to $5,000 per ounce [11] Market Data - The Shanghai Composite Index fell by 0.19%, with sectors like rare earth permanent magnets and gold showing strength, while over 3,600 stocks declined [12] - The financing balance in the two markets decreased by 34.95 billion yuan as of October 10, 2023 [13] - The Hong Kong Hang Seng Index dropped by 1.52%, with significant movements in the gold and semiconductor sectors [14] Company Dynamics - Microsoft will stop providing security updates and technical support for Windows 10 starting October 14, 2023, urging users to upgrade to Windows 11 [16] - Boehringer Ingelheim announced the launch of local production for its diabetes medication in China, enhancing supply stability in the market [17] - Meituan introduced a "full refund for side effects" feature for certain medications, allowing users to return products if they experience adverse effects within 21 days [18]

Core Insights - China National Pharmaceutical Group's self-developed drug TQB2102 has been included in the Breakthrough Therapy Designation (BTD) program by the National Medical Products Administration (NMPA) for the treatment of HER2 IHC 3+ advanced colorectal cancer that has failed previous treatments with oxaliplatin, irinotecan, and fluorouracil [1][2] - TQB2102 is a dual-targeting antibody-drug conjugate (ADC) that targets HER2 protein ECD2 and ECD4 non-overlapping epitopes, showing significant efficacy in colorectal cancer treatment [1] - Preliminary data from the Phase I clinical trial presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting indicates an objective response rate (ORR) of 34.8% in patients with HER2 high expression (HER2 IHC 3+) [1] Industry Context - There is currently a lack of specific targeted treatment options for advanced colorectal cancer with HER2 overexpression, with existing second-line treatments showing low efficacy [2] - The objective response rate (ORR) for third-line treatment options is only 1.0%-2.0%, with progression-free survival (PFS) ranging from 1.9 to 3.7 months and overall survival (OS) between 6.4 to 7.4 months, highlighting the urgent need for effective treatment solutions [2] - The inclusion of TQB2102 in the BTD program is expected to accelerate its market entry, potentially transforming the treatment landscape for HER2 IHC 3+ colorectal cancer [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 資料來源： TQB2102「HER2雙抗ADC」納入突破性治療藥物程序 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的國家1類新藥注射用TQB2102「HER2雙特異性抗體偶聯藥物(ADC)」已被中國國家藥品監督 管理局藥品審評中心(CDE)納入突破性治療藥物程序(BTD)，用於既往經奧沙利鉑、伊立替康、氟尿 嘧啶類藥物治療失敗的HER2 IHC 3+晚期結直腸癌的治療。 自願公告 TQB2102是一款同時靶向HER2蛋白ECD2及ECD4雙非重疊表位的雙抗ADC藥物，憑藉差異化的 設計在結腸癌治療中顯示出強效優勢。本集團已在2025年美國臨床腫瘤學會(ASCO)年會上公佈了 TQB2102的I期臨床研究初步數據[1]。截至2024年10 ...

来源：市场资讯 （来源：真灼财经） 美股三大指数上周五急挫，道指跌878点或1.9%，标普500指数及纳指跌幅更分别达到2.7%及3.6%。反 映中概股表现之金龙指数亦急跌超过6%。 中港股市上周五同样下跌，A股方面，上综指及深成指分别下跌近1%及2.7%，不过全周计则上综指升 0.37%，深成指跌1.3%。至于港股连续第五个交易日下跌，当中上周五跌幅亦较显著，受科技股跌势拖 累，恒指最终收报26,290点，下跌462点或1.7%，科指跌幅则达到3.3%，收报6,259点。全周计则恒指及 科指分别累跌3.1%及5.5%。成份股中以中芯(00981.HK)表现最差，虽然周中一度创下93.5元新高，但周 四由升转跌后周五跌势加剧，最终一周累跌达到14.7%，另外阿里巴巴(09988.HK)及药明生物 (02269.HK)跌幅均超过一成，值得留意是药股上周跌势显著，中生制药(01177.HK)及药明康得 (02359.HK)跌幅亦超过7%。至于表现最好成份股则是获汇控(00005.HK)提出私有化之恒生(00011.HK)， 股价一周劲升逾26%，至于汇控则跌近6%。另外个别地产股亦有不俗表现，恒隆地产(00101 ...

Core Insights - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index has decreased by 3.79% as of October 13, 2025, with notable declines in stocks such as Junshi Biosciences down 10.01% and Innovent Biologics down 7.08% [3] - The Hong Kong Innovative Drug Selection ETF (520690) has also fallen by 3.54%, currently priced at 0.95 yuan, indicating a challenging market environment for innovative drug companies [3] - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, where breakthrough data from various Chinese innovative drug companies is anticipated [3] Company Developments - Rongchang Biopharmaceutical's Taitasip has been proposed for priority review by China's drug regulatory authority, targeting adult patients with IgA nephropathy [4] - Innovent Biologics has initiated Phase III clinical trials for IBI363, aimed at squamous non-small cell lung cancer [4] - SystImmune, a wholly-owned subsidiary of Bai Li Tianheng, has entered a global strategic collaboration with Bristol-Myers Squibb for the dual antibody ADC project, triggering an initial payment of $250 million [4] Market Trends - The trend of Chinese innovative drugs entering international markets is expected to continue, with 72 license-out transactions recorded in the first half of 2025, surpassing the total for 2024 [4] - The total transaction amount for these deals has increased by 16% compared to the entirety of 2024, with 16 transactions exceeding $1 billion [4] - Despite concerns over trade tensions and potential decoupling, the shift of global innovative research and development towards China is viewed as an unstoppable trend [4] ETF Performance - The Hong Kong Innovative Drug Selection ETF has reached a new high with 431 million shares outstanding [5] - Recent net inflows into the ETF amount to 3.01 million yuan, with a total of 75.52 million yuan net inflow over the past 14 trading days [5] - The ETF closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, which reflects the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5]

Core Points - Boehringer Ingelheim has officially launched the local production of its diabetes drug, Onglyza (linagliptin), in China, marking the company's first local production of a human medication in the country [1] - The local production plan is expected to significantly enhance the supply stability of Onglyza in the Chinese market [1] - The CEO of China National Pharmaceutical Group, Xie Chengrun, attended the launch ceremony, indicating a partnership between Boehringer Ingelheim and the Chinese biopharmaceutical company [1]

Market Overview - Global markets experienced a decline, with the Hang Seng Index dropping by 1.73% and the Nasdaq falling by 3.56% [1][3] - The Chinese stock market faced significant pullbacks due to escalating trade tensions with the U.S., leading to increased risk aversion among investors [3] Industry Insights - The Chinese pharmaceutical sector has seen a 74.9% increase in the MSCI China Healthcare Index since early 2025, outperforming the MSCI China Index by 35.8% [4] - Recent pullbacks in the healthcare sector present buying opportunities, driven by a recovery in capital market financing and an increase in demand for innovative drug development [4][6] - The market is advised to focus on the clinical progress of authorized innovative drug pipelines overseas, which could enhance their value [4] Company Analysis - China Biologic Products (1177 HK) has shown promising results with its PDE3/4 inhibitor TQC3721 in Phase II clinical trials, indicating significant potential for improving lung function in COPD patients [6][7] - TQC3721 demonstrated a peak FEV1 improvement of 147ml compared to the placebo group, suggesting its potential as a leading treatment option in the COPD market [8][9] - The global COPD market is substantial, with nearly 480 million affected individuals, highlighting the significant market potential for TQC3721 [9] - China Biologic Products maintains a "Buy" rating with a target price of HKD 9.40, anticipating revenue growth rates of +19.1% for 2025 [10]